{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-025737","form_type":"8-K/A","ticker":"PTIX","cik":"0001022899","company_name":"Protagenic Therapeutics, Inc.new","filed_at":"2025-08-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.144326+00:00","generated_at":"2026-05-17T09:22:57.389552+00:00","sec_items":["9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Protagenic restructures after Phytanix acquisition; CEO/COO out, targets $8M savings","bullets":["Acquired Phytanix Bio on May 15, 2025 via share exchange; gained five preclinical candidates (PHYX-001 to -005).","On Aug 8, Board approved restructuring: suspended preclinical programs, terminated CEO Barrett Evans and COO Colin Stott.","Restructuring expected to cut annual operating expenses by ~$8M; focus on Phase 2 trial of PT00114.","Changed auditor from MaloneBailey to GreenGrowth CPAs; fiscal year changed from Dec 31 to March 31, effective Aug 7, 2025.","Historical Phytanix loss from ops $2.6M for year ended Mar 31, 2025; cash used in ops $1.8M; ~$1M ATM capacity remains."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-025737","json":"https://secwatch.observer/filing/0001641172-25-025737.json","markdown":"https://secwatch.observer/filing/0001641172-25-025737.md","text":"https://secwatch.observer/filing/0001641172-25-025737.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1022899/000164117225025737/0001641172-25-025737-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1022899/000164117225025737/form8-ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T09:22:57.389552+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}